Arcellx (ACLX) Stock Forecast, Price Target & Predictions
ACLX Stock Forecast
Arcellx stock forecast is as follows: an average price target of $83.00 (represents a -5.50% downside from ACLX’s last price of $87.83) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
ACLX Price Target
ACLX Analyst Ratings
Buy
Arcellx Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 08, 2024 | Biren Amin | Piper Sandler | $115.00 | $101.09 | 13.76% | 30.93% |
Nov 06, 2024 | Jack Allen | Robert W. Baird | $106.00 | $86.08 | 23.13% | 20.69% |
Nov 06, 2024 | Emily Bodnar | H.C. Wainwright | $95.00 | $86.08 | 10.36% | 8.16% |
Oct 29, 2024 | Cory Kasimov | Evercore ISI | $120.00 | $84.99 | 41.19% | 36.63% |
Oct 18, 2024 | Ben Burnett | Stifel Nicolaus | $122.00 | $95.27 | 28.06% | 38.90% |
May 31, 2024 | Biren Amin | Piper Sandler | $70.00 | $52.24 | 34.00% | -20.30% |
May 15, 2024 | Benjamin Burnett | Stifel Nicolaus | $83.00 | $50.62 | 63.97% | -5.50% |
May 13, 2024 | Cory Kasimov | Evercore ISI | $85.00 | $49.77 | 70.79% | -3.22% |
Mar 18, 2024 | Gil Blum | Needham | $81.00 | $69.11 | 17.20% | -7.78% |
Dec 12, 2022 | - | Needham | $35.00 | $28.84 | 21.34% | -60.15% |
10
Arcellx Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 5 | 5 | 9 |
Avg Price Target | $111.60 | $111.60 | $97.44 |
Last Closing Price | $87.83 | $87.83 | $87.83 |
Upside/Downside | 27.06% | 27.06% | 10.94% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Nov 06, 2024 | Citigroup | Buy | Buy | Hold |
Nov 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Nov 05, 2024 | Bank of America Securities | Buy | Buy | Hold |
Oct 29, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Oct 18, 2024 | Needham | Buy | Buy | Hold |
Sep 03, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
Jul 22, 2024 | Piper Sandler | Buy | Buy | Hold |
Jul 22, 2024 | Needham | Underperform | Underperform | Hold |
Jun 18, 2024 | Piper Sandler | Buy | Buy | Hold |
10
Arcellx Financial Forecast
Arcellx Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $63.15M | $14.96M | $14.30M | $17.91M | - |
Avg Forecast | $100.60M | $85.80M | $26.03M | $26.03M | $34.43M | $22.31M | $21.25M | $21.25M | $25.47M | $38.73M | $22.04M | $20.67M | $20.07M | $17.49M | $39.29M | $100.97M | $3.00M |
High Forecast | $137.82M | $117.55M | $35.66M | $35.66M | $47.17M | $30.57M | $29.12M | $23.19M | $34.39M | $38.87M | $22.04M | $20.67M | $25.12M | $17.92M | $53.83M | $138.33M | $4.11M |
Low Forecast | $71.37M | $60.87M | $18.47M | $18.47M | $24.43M | $15.83M | $15.08M | $19.32M | $15.99M | $38.59M | $22.04M | $20.67M | $15.07M | $17.07M | $27.88M | $71.64M | $2.13M |
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.15% | 0.86% | 0.36% | 0.18% | - |
Forecast
Arcellx EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $35.76M | $-44.86M | $-29.56M | $-25.56M | $-35.29M |
Avg Forecast | $68.78M | $58.66M | $17.80M | $17.80M | $23.54M | $15.26M | $14.53M | $14.53M | $17.42M | $26.48M | $15.07M | $14.13M | $13.72M | $11.96M | $26.86M | $69.04M | $2.05M |
High Forecast | $94.23M | $80.37M | $24.38M | $24.38M | $32.25M | $20.90M | $19.91M | $15.85M | $23.51M | $26.57M | $15.07M | $14.13M | $17.18M | $12.25M | $36.80M | $94.58M | $2.81M |
Low Forecast | $48.80M | $41.62M | $12.63M | $12.63M | $16.70M | $10.82M | $10.31M | $13.21M | $10.94M | $26.38M | $15.07M | $14.13M | $10.31M | $11.67M | $19.06M | $48.98M | $1.46M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.61% | -3.75% | -1.10% | -0.37% | -17.20% |
Forecast
Arcellx Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $19.52M | $-39.34M | $-23.85M | $-27.34M | $-37.41M |
Avg Forecast | $-38.79M | $-43.67M | $-53.82M | $-50.36M | $-31.35M | $-39.06M | $-38.08M | $-34.78M | $-30.14M | $-16.67M | $-27.93M | $-27.33M | $-28.66M | $-29.58M | $-39.55M | $98.06M | $-52.50M |
High Forecast | $-24.14M | $-27.18M | $-33.49M | $-31.34M | $-19.51M | $-24.31M | $-23.70M | $-25.30M | $-590.95K | $-10.37M | $-17.38M | $-17.01M | $-14.56M | $-18.41M | $-24.61M | $145.23M | $-32.67M |
Low Forecast | $-57.45M | $-64.68M | $-79.70M | $-74.58M | $-46.43M | $-57.85M | $-56.40M | $-41.11M | $-52.00M | $-24.68M | $-41.36M | $-40.48M | $-50.05M | $-43.80M | $-58.57M | $61.03M | $-77.76M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.68% | 1.33% | 0.60% | -0.28% | 0.71% |
Forecast
Arcellx SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $19.37M | $16.01M | $15.54M | $15.44M | $14.06M |
Avg Forecast | $92.58M | $78.96M | $23.96M | $23.96M | $31.68M | $20.54M | $19.56M | $19.56M | $23.44M | $35.64M | $20.28M | $19.02M | $18.47M | $16.10M | $36.16M | $92.92M | $2.76M |
High Forecast | $126.84M | $108.18M | $32.82M | $32.82M | $43.41M | $28.13M | $26.80M | $21.34M | $31.65M | $35.77M | $20.28M | $19.02M | $23.12M | $16.49M | $49.54M | $127.31M | $3.78M |
Low Forecast | $65.68M | $56.02M | $17.00M | $17.00M | $22.48M | $14.57M | $13.88M | $17.78M | $14.72M | $35.51M | $20.28M | $19.02M | $13.87M | $15.71M | $25.65M | $65.93M | $1.96M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 0.99% | 0.43% | 0.17% | 5.09% |
Forecast
Arcellx EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.58 | $-1.03 |
Avg Forecast | $-0.72 | $-0.81 | $-1.00 | $-0.94 | $-0.58 | $-0.73 | $-0.71 | $-0.65 | $-0.56 | $-0.31 | $-0.52 | $-0.51 | $-0.53 | $-0.55 | $-0.73 | $1.82 | $-0.98 |
High Forecast | $-0.45 | $-0.50 | $-0.62 | $-0.58 | $-0.36 | $-0.45 | $-0.44 | $-0.47 | $-0.01 | $-0.19 | $-0.32 | $-0.32 | $-0.27 | $-0.34 | $-0.46 | $2.70 | $-0.61 |
Low Forecast | $-1.07 | $-1.20 | $-1.48 | $-1.39 | $-0.86 | $-1.07 | $-1.05 | $-0.76 | $-0.97 | $-0.46 | $-0.77 | $-0.75 | $-0.93 | $-0.81 | $-1.09 | $1.13 | $-1.44 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.00% | 0.00% | 0.00% | -0.32% | 1.06% |
Forecast
Arcellx Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
VTYX | Ventyx Biosciences | $1.87 | $33.86 | 1710.70% | Buy |
BMEA | Biomea Fusion | $6.53 | $22.75 | 248.39% | Buy |
DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
NUVL | Nuvalent | $86.88 | $111.57 | 28.42% | Buy |
AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
ACLX | Arcellx | $87.83 | $83.00 | -5.50% | Buy |